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Abstract
We prospectively studied the consequences of extensive antibiotic treatment on faecal car-
riage of antibiotic-resistant enterobacteria in a cohort of children with cystic fibrosis (CF)
and a cohort of children with cancer compared to healthy children with no or low antibiotic
exposure. The study was conducted in Norway in a low resistance prevalence setting. Sixty
longitudinally collected faecal samples from children with CF (n = 32), 88 samples from chil-
dren with cancer (n = 45) and 127 samples from healthy children (n = 70) were examined.
A direct MIC-gradient strip method was used to detect resistant Enterobacteriaceae by
applying Etest strips directly onto agar-plates swabbed with faecal samples. Whole genome
sequencing (WGS) data were analysed to identify resistance mechanisms in 28 multidrug-
resistant Escherichia coli isolates. The prevalence of resistance to third-generation cephalo-
sporins, gentamicin and ciprofloxacin was low in all the study groups. At inclusion the preva-
lence of ampicillin-resistant E. coli and trimethoprim-sulfamethoxazole-resistant E. coli in
the CF group compared to healthy controls was 58.6% vs. 28.4% (p = 0.005) and 48.3% vs.
14.9% (p = 0.001), respectively, with a similar prevalence at the end of the study. The preva-
lence of resistant enterobacteria was not significantly different in the children with cancer
compared to the healthy children, not even at the end of the study when the children with
cancer had been treated with repeated courses of broad-spectrum antibiotics. Children with
cancer were mainly treated with intravenous antibiotics, while the CF group mainly received
peroral treatment. Our observations indicate that the mode of administration of antibiotics
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and the general level of antimicrobial resistance in the community may have an impact on
emergence of resistance in intestinal enterobacteria during antibiotic treatment. The WGS
analyses detected acquired resistance genes and/or chromosomal mutations that explained
the observed phenotypic resistance in all 28 multidrug-resistant E. coli isolates examined.
Introduction
The worldwide increasing prevalence of antimicrobial resistance with decreased access to
effective antimicrobials has become one of the biggest health care challenges of our time [1, 2].
Use and overuse of antibiotics in humans is one of the main drivers of antibiotic resistance
although the relationship between human antimicrobial usage and resistance is complex [3, 4].
Several studies have documented an association between antibiotic use in humans and the
development of resistance both at a population level and in individuals [5–7].
During antibiotic treatment both pathogens and commensals are exposed to antibiotics.
Several studies have shown effects of antibiotic treatment on the human gut flora [8–10],
including selection of antibiotic-resistant enterobacteria [11]. Resistant endogenous entero-
bacteria may cause infections that are difficult to treat, and the gut microbiota may serve as a
reservoir for antibiotic resistance genes [12, 13]. These resistance genes may spread between
bacterial strains and species within the microbiome [14–16], between individuals, and to the
environment [17, 18].
The studies on effects of antibiotic treatment on intestinal bacteria have mainly revealed an
increased level of resistance during and after single courses of treatment [8, 11]. The studies
show that after antibiotic treatment, the susceptibility either returns to baseline levels shortly
after the cessation of therapy [11, 19], or there is a prolonged effect even after single courses
[20–22]. Given the fact that systematic, longitudinal studies of the consequences of long-time
extensive antibiotic exposure in infants and children are lacking, we have investigated the fae-
cal flora in children with cystic fibrosis (CF) and cancer, two patient groups known to receive
much antibiotic treatment. Healthy children were included as a control group. The prevalence
of antibiotic resistance was low in Norway during the study period [23].
CF is an inherited disease caused by mutations in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene leading to altered ion and water transport across apical cell mem-
branes in exocrine glands [24]. Viscous airway secretions and reduced mucociliary clearance
lead to frequent and chronic lung infections. Consequently, CF patients are repeatedly treated
with antibiotics from early childhood [25, 26]. Children with cancer are often treated with che-
motherapy that causes immunosuppression including neutropenia. This entails an increased
risk of severe invasive infections requiring repeated courses with broad-spectrum antibiotics.
The primary aim of this study was to investigate whether the prevalence of faecal carriage of
antibiotic-resistant enterobacteria is higher in children with CF or cancer compared to healthy
children with low antibiotic exposure in Norway. The secondary aim was to explore the
genetic determinants conferring antibiotic resistance in intestinal enterobacteria isolated from
these children.
Materials and methods
Study design, participants and clinical information
Serial faecal samples were collected from children with CF (n = 32, 2004–2007) and children
with cancer (n = 45, 1999–2000 and 2003–2005) treated at Oslo University Hospital, Oslo,
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Norway and from 70 healthy children in day-care centres and schools in Oslo (2000–2001 and
2006–2008). Age and gender distributions are shown in Table 1. CF patients were consecu-
tively included at regular outpatient visits, and the faecal samples were collected regardless of
clinical condition or on-going antibiotic treatment. Cancer patients were consecutively
included within one week after cancer was diagnosed. The first faecal sample was collected
regardless of prior or on-going antibiotic treatment, since such treatment often was initiated
prior to or shortly after admission to the hospital.
Inclusion criteria were children diagnosed with CF based on clinical symptoms and a posi-
tive sweat test and/or two identified CFTR mutations, children with newly diagnosed cancer
who received treatment with at least one course of anticancer chemotherapy, and healthy chil-
dren with no underlying chronic disease. The cancer diagnoses comprised 19 acute lympho-
blastic leukaemias, six acute myeloblastic leukaemias, six non-Hodgkin lymphomas, four
Wilms tumours, two primitive nevroectodermal tumours, and one each of ependymoma,
Ewing sarcoma, germinal cell tumour, Hodgkin lymphoma, opticus glioma, rhabdomyosar-
coma, rhabdoid kidney tumour and spindle-celled sarcoma.
For children with CF and cancer, the medical records were reviewed for antibiotic treat-
ment during the study period. In addition, parents in all three study groups were asked about
previous antibiotic treatment. Written, informed consent was obtained from the participants’
parents and from the participants themselves when 12 years or older. The study was approved
by the Regional Committee for Medical and Health Research Ethics–South East (“REK sør-
øst”) (reference number 581-06-03092).
Detection of resistant Enterobacteriaceae in faecal samples
The faecal samples were directly mixed with Carey-Blair transport medium and either sent by
mail or personally delivered to the laboratory. The samples were then plated out on lactose
agar plates and incubated at 35˚C (0–5 days after sampling). Bacterial growth (mainly Entero-
bacteriaceae) was noted, and morphologically different colonies were selected and identified.
Both primary growth and the identity of the selected bacteria were recorded for each sample.
Furthermore, the pure cultures and the faecal samples, mixed with Greaves‘freezing medium,
were frozen consecutively at -80˚C. For the present study a direct MIC-gradient strip method,
recently described by Gammelsrud et al. [27], was used to detect resistant Enterobacteriaceae
in the faecal samples. In short, the stool sample suspensions were thawed and swabbed directly
onto two 14 cm diameter Mueller-Hinton agar plates (Becton Dickinson, Sparks, MD, USA).
Six MIC-gradient strips (Etest, bioMeriéux, Marcy L’Étoile, France) were subsequently applied
directly onto each plate. The following 12 antibiotics were used; ampicillin, aztreonam, cefo-
taxime, cefoxitin, ceftazidime, ciprofloxacin, colistin, gentamicin, imipenem, tetracycline,
Table 1. Background information and faecal sample information on the children with cystic fibrosis, the children with cancer and the healthy
children.
Cystic fibrosis (n = 32) Cancer (n = 45) Healthy controls (n = 70) p-values
CF vs. HC C vs. HC
Age (year) [median (range) ] 5.9 (0.9–16.3) 4.3 (0.3–14.1) 5.5 (0.5–15.5) 0.91 0.23
Female gender [n (%)] 15 (46.9) 23 (51.1) 38 (54.3) 0.49 0.74
Months between first and last sample [median (range)] 9.1 (4.2–22.1) 8.0 (1.5–16.4) 13.4 (3.0–26.0) 0.02 <0.001
Individuals with two samplesa [n (%)] 28 (87.5) 43 (95.6) 57 (81.4) 0.45 0.03
CF, cystic fibrosis; C, cancer; HC, healthy controls.
a One sample obtained from the remaining individuals.
https://doi.org/10.1371/journal.pone.0187618.t001
Antibiotic treatment and faecal carriage of antibiotic-resistant enterobacteria in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0187618 November 7, 2017 3 / 18
tobramycin and trimethoprim-sulfamethoxazole. All samples were also plated on a lactose
agar plate as growth control for comparison with the initial growth prior to the freezing. All
plates were incubated for 18–24 h at 35˚C in ambient air. Only Gram-negative bacteria were
further studied. In the case of growth within the Etest ellipses (due to assumingly more resis-
tant organisms than the dominant bacterial populations), 1–2 colonies of each morphotype
were selected from the ellipse area for species identification and further susceptibility testing.
To assess the dominant bacterial populations with confluent growth along the Etests, a loop-
full of growth next to the strip at the highest MIC value was inoculated onto a lactose agar
plate. One colony of each morphotype from this growth was also subsequently selected for spe-
cies identification and susceptibility testing. Species identification was done by the three-tube
fermentation method [28] or by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany).
All selected isolates were tested against nine antibiotics (ampicillin, cefotaxime, ceftazidime,
ciprofloxacin, gentamicin, imipenem, meropenem, tetracycline and trimethoprim-sulfameth-
oxazole) by disk diffusion according to EUCAST (v 6.0 2016, www.eucast.org). For isolates
classified as intermediately susceptible, the final susceptibility category was confirmed using
Etest.
Whole genome sequencing (WGS) and assembling
To explore genetic determinants responsible for antibiotic resistance, WGS was applied on 28
Escherichia coli isolates. These were the E. coli isolates from the CF group (n = 10), the cancer
group (n = 5) and the control group (n = 2) displaying phenotypic resistance to one or more of
the following antibiotics: cefotaxime, ceftazidime, ciprofloxacin and gentamicin, and all other
E. coli isolates from the CF group (n = 11) simultaneously resistant to antibiotics from at least
three antimicrobial categories [29].
Genomic DNA was extracted using MagNa Pure 96 (Roche Diagnostics, Mannheim, Ger-
many) according to the manufacturer’s instructions. DNA concentrations were measured
using a Qubit fluorometer (Thermo Fisher Scientific, MA, USA) to determine DNA input for
each isolate. Libraries were prepared using KAPA HyperPlus Library Preparation Kit (Kapa
Biosystems, MA, USA). WGS was performed on the Illumina MiSeq platform using v 2 reagent
kits generating 2x250 bp paired-end reads (Illumina, San Diego, CA, USA). All isolates were
quality corrected and assembled using BayesHammer/SPAdes v 3.6.0. [30]. Assembly informa-
tion about the different isolates can be found in S1 Table.
Identification of genetic resistance determinants and multilocus
sequence typing (MLST) of E. coli
The assembled genomes were submitted to the web-based ResFinder service v 2.1 (Center
for Genomic Epidemiology, DTU, Denmark) to identify acquired resistance genes [31]. Hits
were accepted for matches with 99% nucleotide identity and length of the query sequence
covering 95% of the length of the gene in the database. If acquired resistance genes associ-
ated with the phenotypic resistance of the isolate were not found by ResFinder, Python scripts
were written to extract gyrA, gyrB, parC, parE and ampC genes. The quinolone resistance-
determining regions (QRDRs) of the gyrA, gyrB, parC and parE genes or the promoter and
attenuator regions of the ampC gene, as appropriate, were analysed to identify chromosomal
structural gene mutations by alignment using Seaview v 4.6.1. [32].
MLST of all the sequenced E. coli isolates was performed from WGS data by the web-based
MLST v 1.8 service (Center for Genomic Epidemiology, DTU, Denmark) [33], using two dif-
ferent E. coli MLST schemes [34, 35].
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Identification of resistance mechanisms in Enterobacteriaceae species
other than E. coli
Non-E. coli isolates with reduced susceptibility to third-generation cephalosporins were inves-
tigated for the phenotypic expression of extended-spectrum β-lactamases (ESBLs) and AmpC
using Etest combination gradient-strips (bioMeriéux, Marcy L’Étoile, France), combination
discs (AmpC confirm ID kit, Rosco Diagnostica, Taastrup, Denmark) and BD ESBL discs (BD
Diagnostic Systems, Sparks, USA).
Statistics
Pearson’s chi-square test was used when comparing categorical data in two groups, but
Fischer’s exact test was used when the overall sample size was <40 and the smallest expected
number was<5 in the 2x2 table analysis. Independent samples t-test was used when compar-
ing normally distributed continuous data in two groups (SPSS software, v 22.0). The signifi-
cance level was set to 5%.
Results
Faecal samples and enterobacterial species distribution
The total number of faecal samples collected from each participant differed from one to 15
(median three). From some of the samples there was no growth of Gram-negative enterobacte-
ria despite several attempts to inoculate the faecal specimens on different agars, possibly due to
recent or on-going antibiotic exposure. For this study, the first and the last faecal sample that
showed growth of Enterobacteriaceae from each participant were included. From four children
with CF, two children with cancer and 13 healthy controls, we either received only one faecal
sample or only one of the submitted samples showed enterobacterial growth. In all, 29 CF
patients, 44 cancer patients and 67 healthy controls submitted samples with growth of entero-
bacteria at the time of inclusion (first sample), whereas 31 CF patients, 44 cancer patients and
60 controls submitted samples with enterobacterial growth at the end of the study period (last
sample). Sample information is presented in Table 1.
The observed growth of enterobacteria on the lactose agar after storage of the faecal samples
was in high agreement with the primary growth before freezing of the samples.
From each sample, 0–5 phenotypically different isolates of Enterobacteriaceae species were
detected. The proportions of the faecal samples from the three study groups with growth of dif-
ferent enterobacterial species are shown in Table 2.
Antibiotic consumption
Children with CF or cancer. Children in both patient groups received numerous antibi-
otic courses during the study period, but the treatment pattern differed significantly between
these two groups, as shown in Fig 1. For detailed information, see S2 Table. Aminopenicillin
was almost exclusively administered intravenously (ampicillin) to the cancer patients, whilst
given orally (amoxicillin) to the CF patients. Seventy percent of the cancer patients received
prophylaxis against Pneumocystis jirovecii with trimethoprim-sulfamethoxazole 2–3 days per
week. Prophylactic treatment was not given to any CF patient. Five of the CF patients were
treated with inhaled tobramycin while six received inhaled colistin during the study period.
No cancer patient received inhaled antibiotics. Parents of cancer patients reported antibiotic
treatment before the cancer diagnosis for 26 of the 45 children (58%). Eight of them were
treated within two months prior to inclusion in the study, and 33 cancer patients received anti-
biotics after study inclusion, but prior to the first faecal sample. This treatment is included in
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Fig 1 and S2 Table. All the CF patients had received multiple courses of antibiotics prior to the
study, but this is not included in Fig 1 and S2 Table.
Healthy controls. According to parental information, a total of 37 of the 70 healthy chil-
dren (53%) had never been treated with antibiotics prior to or during the study period. The
remaining 33 children had received mainly a single course or a few courses of peroral
Table 2. Growth of different Enterobacteriaceae species in faecal samples from 32 children with cystic fibrosis, 45 children with cancer and 70
healthy childrena.
CF, n/N (%) Cancer, n/N (%) Healthy controls, n/N (%) p-values
CF vs. HC C vs. HC
E.coli
First sample 26/29 (89.7) 41/44 (93.2) 63/67 (94.0) 0.45 0.86
Last sample 30/31 (96.8) 37/44 (84.1) 58/60 (96.7) 0.98 0.02
Klebsiella spp.
First sample 17/29 (58.6) 15/44 (34.1) 14/67 (20.9) <0.001 0.12
Last sample 16/31 (51.6) 13/44 (29.5) 9/60 (15.0) <0.001 0.07
Enterobacter spp.
First sample 9/29 (31.0) 10/44 (22.7) 8/67 (11.9) 0.02 0.13
Last sample 8/31 (25.8) 12/44 (27.3) 10/60 (16.7) 0.30 0.19
Citrobacter spp.
First sample 5/29 (17.2) 5/44 (11.4) 11/67 (16.4) 0.92 0.46
Last sample 8/31 (25.8) 6/44 (13.6) 9/60 (15.0) 0.21 0.85
Other Enterobacteriaceae spp.b
First sample 9/29 (31.0) 3/44 (6.8) 8/67 (11.9) 0.02 0.38
Last sample 9/31 (29.0) 6/44 (13.6) 2/60 (3.3) <0.001 0.05
CF, cystic fibrosis; C, cancer; HC, healthy controls.
a The total number (N) of first samples and last samples differ within each study group because some individuals submitted only one faecal sample with
enterobacterial growth, either at the inclusion or at the end of the study period.
b Hafnia alvei, Proteus spp., Morganella morganii, Yersinia enterocolitica, Kluyvera intermedia
https://doi.org/10.1371/journal.pone.0187618.t002
Fig 1. Antibiotic treatment in 31 children with cystic fibrosis (CF) and 44 children with cancer. (A)
Median (range, shown inside the columns) number of days per calendar year with antibiotic treatment in the
study period among patients who received at least one course of treatment. For some antibiotics, median
number of days is not shown (NS) due to no or only one or two patients treated. (B) Number of patients (%) in
each patient group treated with at least one course of the antibiotic. For one of the 32 CF patients and for one
of the 45 cancer patients included in the study no antibiotic treatment was registered since a faecal sample
was provided only at the time of inclusion into the study. ^Amoxicillin was only administered orally and
ampicillin was only administered intravenously. *Prophylactic treatment given to cancer patients is not
included.
https://doi.org/10.1371/journal.pone.0187618.g001
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phenoxymethylpenicillin, amoxicillin or erythromycin. The antibiotic treatment in each of the
healthy children is shown in S3 Table. Nine (13%) of the healthy children had received antibi-
otic treatment within a year before the first study sample, including four treated during the last
two months. Five children (7.1%) received antibiotics during the study period including four
less than one year but only one less than two months prior to the last sample.
Prevalence of antibiotic resistance
Table 3 shows the prevalence of E. coli and all enterobacterial species combined (including E.
coli) resistant to the antibiotics tested in the two faecal samples from our three study groups.
No significant difference between the first and the last sample was observed for any of the
tested antibiotics in any of the three groups.
Children with cancer. The prevalence of E. coli and all Enterobacteriaceae species com-
bined, resistant to the antibiotics tested was not significantly different in the children with can-
cer compared to the healthy children in any of the two samples (Table 3).
Children with CF. The prevalence of ampicillin-resistant and trimethoprim-sulfamethox-
azole-resistant E. coli and Enterobacteriaceae species combined was significantly higher in the
CF group compared to the healthy children (Table 3).
Within the CF group the relative risk (RR) of harbouring trimethoprim-sulfamethoxazole-
resistant Enterobacteriaceae in the last faecal sample was 1.83 (95%CI 1.11–3.02) in those
treated with trimethoprim-sulfamethoxazole during the last 60 days compared to those not
treated. Other statistically significant correlations between antibiotic exposure and antibiotic
resistance were not found for any antibiotics in any of the two patient groups.
Healthy controls. Enterobacteria with resistance to the same type of antibiotic that the
children had been treated with, were detected in only three of the 13 samples that were col-
lected from the healthy children less than one year after the antibiotic treatment. These were
ampicillin-resistant E. coli isolates detected in samples from children that had received
amoxicillin.
No carbapenem-resistant E. coli or other Enterobacteriaceae species were found in any of
the three study groups.
The prevalence of E. coli resistant to ampicillin and trimethoprim-sulfamethoxazole was
not significantly different in children younger than four years compared to children older than
four years in any of the three study groups (Table 4). A shift in ampicillin and trimethoprim-
sulfamethoxazole susceptibility in E. coli between the first and the last sample (resistant isolates
detected in the last sample but not in the first sample or vice versa) was observed in children
from all the study groups (Table 5).
Antibiotic resistance mechanisms
To investigate the mechanisms behind the observed resistance in E. coli isolates, 28 isolates
were genome sequenced and WGS data were analysed for acquired resistance genes and spe-
cific chromosomal mutations (Table 6, S4 Table). Resistance to ampicillin and third-genera-
tion cephalosporins was mainly due to the presence of narrow-spectrum β-lactamases (blaTEM-
1), ESBLs (blaCTX-M-1 and blaSHV-2) or plasmid-mediated AmpC (blaCMY-7) [36]. In two iso-
lates resistant to third-generation cephalosporins, but devoid of acquired ESBLs, previously
described blaAmpC promoter mutations (-42:C->T and -18:G->A) [37] were identified. One
or two dfrA genes in combination with one or two sul genes were found in all isolates resistant
to trimethoprim-sulfamethoxazole [38] and at least one of the tetracycline efflux genes tet(A),
tet(B) or tet(D) were found in all tetracycline-resistant isolates [39]. Two gyrA mutations (Ser-
83-Leu and Asp-87-Asn) and at least one parC mutation (Ser-80-Ile or Glu-84-Val) were
Antibiotic treatment and faecal carriage of antibiotic-resistant enterobacteria in children
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Table 3. Prevalence of antibiotic-resistant isolates of Escherichia coli and all Enterobacteriaceae species combined (including E. coli) in the first
and the last faecal sample from children with cystic fibrosis, cancer and healthy controls (one or more resistant isolates per sample)a.
CF, n/N (%) Cancer, n/N (%) Healthy controls, n/N (%) p-values
CF vs. HC C vs. HC
Ampicillin
E. coli
First sample 17/29 (58.6) 12/44 (27.3) 19/67 (28.4) 0.005 0.90
Last sample 19/31 (61.3) 17/44 (38.6) 20/60 (33.3) 0.01 0.58
All Enterobacteriaceae spp.
First sample 24/29 (82.8) 27/44 (61.4) 36/67 (53.7) 0.007 0.43
Last sample 28/31 (90.3) 29/44 (65.9) 34/60 (56.7) 0.001 0.34
Trimethoprim-sulfamethoxazole
E. coli
First sample 14/29 (48.3) 8/44 (18.2) 10/67 (14.9) 0.001 0.65
Last sample 14/31 (45.2) 12/44 (27.3) 11/60 (18.3) 0.007 0.28
All Enterobacteriaceae spp.
First sample 15/29 (51.7) 9/44 (20.5) 10/67 (14.9) <0.001 0.45
Last sample 18/31 (58.1) 14/44 (31.8) 11/60 (18.3) <0.001 0.11
Tetracycline
E. coli
First sample 13/29 (44.8) 9/44 (20.5) 15/67 (22.4) 0.03 0.81
Last sample 9/31 (29.0) 9/44 (20.5) 16/60 (26.7) 0.81 0.46
All Enterobacteriaceae spp.
First sample 16/29 (55.2) 12/44 (27.3) 17/67 (25.4) 0.005 0.82
Last sample 14/31 (45.2) 11/44 (25.0) 18/60 (30.0) 0.07 0.57
Cefotaxime and/or Ceftazidime
E.coli
First sample 1/29 (3.4) 2/44 (4.5) 0/67 0.13 0.08
Last sample 2/31 (6.5) 1/44 (2.3) 0/60 <0.05 0.24
All Enterobacteriaceae spp.
First sample 1/29 (3.4) 4/44 (9.1) 3/67 (4.5) 0.82 0.33
Last sample 2/31 (6.5) 4/44 (9.1) 3/60 (5.0) 0.77 0.41
Ciprofloxacin
E.coli
First sample 2/29 (6.9) 1/44 (2.3) 1/67 (1.5) 0.16 0.76
Last sample 1/31 (3.2) 1/44 (2.3) 0/60 0.16 0.24
All Enterobacteriaceae spp.
First sample 2/29 (6.9) 1/44 (2.3) 1/67 (1.5) 0.16 0.76
Last sample 1/31 (3.2) 1/44 (2.3) 0/60 0.16 0.24
Gentamicin
E.coli
First sample 1/29 (3.4) 1/44 (2.3) 2/67 (3.0) 0.91 0.82
Last sample 1/31 (3.2) 1/44 (2.3) 0/60 0.16 0.24
All Enterobacteriaceae spp.
First sample 1/29 (3.4) 1/44 (2.3) 2/67 (3.0) 0.91 0.82
Last sample 1/31 (3.2) 1/44 (2.3) 0/60 0.16 0.24
CF, cystic fibrosis; C, cancer; HC, healthy controls.
a The total number (N) of first samples and last samples differ within each study group because some individuals submitted only one faecal sample with
enterobacterial growth, either at the inclusion or at the end of the study period.
https://doi.org/10.1371/journal.pone.0187618.t003
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detected in the QRDRs in all seven ciprofloxacin-resistant isolates [40]. No plasmid-mediated
resistance genes associated with quinolone resistance were detected. Variants of aac genes or
the aadB (= ANT(2”)-1a) gene were detected in the gentamicin-resistant isolates [41].
Phenotypic analysis of the identified Enterobacteriaceae species other than E. coli with
reduced susceptibility to third-generation cephalosporins showed that all were negative for the
presence of ESBLs. Details can be found in S5 Table.
The overall prevalence (in the first and/or the last faecal sample) of Enterobacteriaceae car-
rying acquired ESBLs was 1/32 (3.1%) in the CF group and 2/45 (4.4%) in the cancer group.
No ESBL-producing enterobacteria were detected in the healthy control group.
E. coli MLST analyses
MLST data from the 28 sequenced E. coli isolates are shown in S4 Table. Isolates with identical
sequence type (ST69) were detected in samples from two different individuals (both with CF)
on only one occasion. Five isolates carrying blaCTX-M-1 isolated from one single CF patient
comprised three sequence types (STs); two different STs (ST1640 and ST6331) were detected
in the first sample, and the same two STs in addition to a third ST (ST2144) were detected in
the last sample.
Discussion
In this study we compared the prevalence of faecal carriage of resistant enterobacteria in two
different patient groups of children with high antibiotic exposure to a group of healthy chil-
dren with low or no known previous antibiotic exposure. We found the prevalence of
Table 4. Prevalence of ampicillin-resistant and trimethoprim-sulfamethoxazole-resistant E. coli in faecal samples from two age groups (younger
or older than 4 years) of patients with cystic fibrosis, cancer and healthy controls (first study sample).
Antibiotic resistance Study groups < 4 years, n/N (%) > = 4 years, n/N (%) p-value
Ampicillin Cystic fibrosis 7/12 (58.3) 10/17 (58.8) 1.0
Cancer 4/21 (19.0) 8/23 (34.8) 0.24
Healthy controls 6/20 (30.0) 13/47 (27.7) 0.85
Trimethoprim-sulfamethoxazole Cystic fibrosis 6/12 (50.0) 8/17 (47.1) 0.88
Cancer 2/21 (9.5) 6/23 (26.1) 0.16
Healthy controls 2/20 (10.0) 8/47 (17.0) 0.46
https://doi.org/10.1371/journal.pone.0187618.t004
Table 5. Occurrence of shift in ampicillin and trimethoprim-sulfamethoxazole susceptibility in faecal Escherichia coli between the first and the
last faecal sample collected from children with cystic fibrosis, cancer and healthy controls.
No resistant isolates in the first
sample, resistant isolates in the
last sample, n/N (%)
Resistant isolates in the first
sample, no resistant isolates in the
last sample, n/N (%)
Same resistance pattern in




7/28 (25.0) 6/28 (21.4) 15/28 (53.6)
Cancer 8/43 (18.6) 2/43 (4.7) 33/43 (76.7)
Healthy
controls






3/28 (10.7) 5/28 (17.9) 20/28 (71.4)
Cancer 6/43 (14.0) 2/43 (4.7) 35/43 (81.4)
Healthy
controls
8/57 (14.0) 6/57 (10.5) 43/57 (75.4)
https://doi.org/10.1371/journal.pone.0187618.t005
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resistance against ampicillin and trimethoprim-sulfamethoxazole to be significantly higher in
the children with CF compared to the healthy children (Table 3). In the last faecal samples col-
lected at the end of the study, the prevalence of ampicillin-resistant E. coli was 61.3% and the
prevalence of trimethoprim-sulfamethoxazole-resistant E. coli was 45.2% in the CF group, sig-
nificantly higher than in the group of healthy children (33.3% and 18.3%, respectively). Sur-
prisingly, the prevalence of antibiotic-resistant enterobacteria was not significantly different in
the children with cancer as compared to the healthy children, not even at the end of the study
period when the children with cancer had been treated with repeated courses of broad-spec-
trum antibiotics.
The level of enterobacterial resistance was low in Norway in the period the study samples
were collected [23]. The prevalence of resistant faecal E. coli in the group of healthy children in
our study was similar to the level of resistance in clinical E. coli isolates from urinary tract
infections reported from the Norwegian Surveillance System for Antimicrobial Drug Resis-
tance [23]. The prevalence of faecal E. coli resistant to ampicillin, trimethoprim-sulfamethoxa-
zole, tetracycline, ciprofloxacin or third-generation cephalosporins in the control group was
also at the same level as the corresponding pooled prevalence of resistant, faecal E. coli in chil-
dren in countries within the Organisation for Economic Co-operation and Development
(OECD) [22]. Fifty-three percent of the children in the healthy control group had never been
treated with antibiotics and the majority of the other children had received only a single or
very few courses of phenoxymethylpenicillin, amoxicillin or erythromycin more than one year
prior to inclusion in the study, based on the parents reporting of drug use (S3 Table). We
detected enterobacteria that were resistant to the same antibiotic that the child had been
Table 6. Genotypic resistance mechanisms identified in 28 resistant Escherichia coli isolates from faecal samples from children with cystic fibro-
sis (21 isolates), cancer (5 isolates) and healthy children (2 isolates).




28 ampicillin-resistant (21 CF, 5 C,
2 HC), 10 third-generation
cephalosporin-resistant (6 CF, 4
C)
blaTEM-1 (21 isolates), blaCTX-M-1 (5
isolates)a, blaSHV-2 (1 isolate), blaCMY-7
(2 isolates)b




22 (18 CF, 3 C, 1 HC) dfrA1 (5 isolates), dfrA7 (3 isolates),
dfrA12 (1 isolate), dfrA14 (3 isolates),
dfrA17 (12 isolates)c + sul1 (16 isolates),
sul2 (19 isolates)d
Tetracycline 21 (17 CF, 2 C, 2 HC) tet(A) (14 isolates), tet(B) (7 isolates), tet
(D) (2 isolates)e
Gentamicin 7 (2 CF, 3 C, 2 HC) aac(3)-IIa (1 isolate), aac(3)-IId (4
isolates)b, aac(3)-IVa (1 isolate), aadB (1
isolate)
Ciprofloxacin 7 (3 CF, 3 C, 1 HC) 2 gyrA mutations: Ser-83-Leu, Asp-87-Asn (7
isolates)b + 1 parC mutation: Ser-80-Ile (6
isolates)b or 2 parC mutations: Ser-80-Ile, Glu-
84-Val (1 isolate)
CF, cystic fibrosis; C, cancer; HC, healthy children
a The five isolates harbouring the blaCTX-M-1 gene were isolated from one CF patient and represented two different E. coli sequence types (STs) from the
first faecal sample and the same two STs plus an additional ST from the last sample collected.
b Two of the isolates from one cancer patient represented the same E. coli ST but with different tetracycline susceptibility patterns.
c Two different dfrA genes were found in two of the isolates.
d Both the sul1 and the sul2 gene were found in 13 of the isolates.
e Two different tet genes were found in two of the isolates.
Detailed information about each of the isolates can be found in S4 Table.
https://doi.org/10.1371/journal.pone.0187618.t006
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treated with in only three of the 13 faecal samples that were collected less than one year after
antibiotic exposure. Thus, it seems that this previous, often Gram-positive spectrum, antibiotic
treatment had little or no impact on the overall level of antibiotic resistance in the group of
healthy children, justifying the use of these children as a control group in our study. We found
no significant difference in the prevalence of ampicillin- and trimethoprim-sulfamethoxazole-
resistant E. coli when we compared children younger or older than four years of age within any
of our three study groups, indicating that resistant faecal E. coli is established at an early age, in
accordance with previous studies [42–44].
In one small study the prevalence of amoxicillin-resistant Enterobacteriaceae in faecal sam-
ples from two children with CF was higher than in samples from their healthy siblings [45].
Only two other studies have investigated the prevalence of resistant faecal enterobacteria in
CF patients, reporting no increase in resistance after treatment with ciprofloxacin and ceftazi-
dime, respectively [46, 47]. Other studies, in other patient groups or healthy volunteers, have
reported an increase in resistant bacteria in stools after antibiotic exposure [8, 11, 22, 48]. The
significantly higher prevalence of ampicillin- and trimethoprim-sulfamethoxazole-resistant
enterobacteria in CF patients in our study is likely due to their large exposure to these antibiot-
ics; 55% of the CF patients were treated with per oral amoxicillin for a median of 19 days per
calendar year during the study period, and 65% were treated with trimethoprim-sulfamethoxa-
zole for a median of 60 days. We also found a relative risk (RR) of 1.83 (95%CI 1.11–3.02) for
carrying trimethoprim-sulfamethoxazole-resistant enterobacteria in the last faecal sample in
CF patients treated with trimethoprim-sulfamethoxazole within the last 60 days as compared
to those not treated. Selection of resistant bacteria during antibiotic treatment is the most likely
mechanism causing the higher presence of resistant faecal enterobacteria in children with CF,
and facilitation of horizontal transfer of resistance genes during antibiotic exposure may also
have occurred [15, 49].
Most of our CF patients had received substantial amounts of antibiotics prior to inclusion
in the study. This may explain why the prevalence of resistance was at the same level in the
first and last sample in the CF group (Table 3). However, a shift in susceptibility patterns
between the first and the last sample was noticed for ampicillin-resistant and trimethoprim-
sulfamethoxazole-resistant E. coli in children from all three study groups (Table 5). This
reflects the dynamic nature of the faecal flora and clearly underlines the importance of longitu-
dinal studies.
Although 84% of the children with cancer were treated with intravenous ampicillin for a
median of 29 days per year during the study period, the occurrence of ampicillin resistance
was not significantly higher in the cancer patients as compared to the healthy controls at the
end of the study period. This may indicate that aminopenicillin administered intravenously
has only a modest effect on selection of intestinal resistance and possibly less impact than oral
administration, which was the main route of administration of aminopenicillin to children
with CF (Fig 1, S2 Table). This is supported by Zhang et al. who demonstrated a much greater
increase of faecal, resistant bacterial populations in mice after oral ampicillin administration
compared to intravenous administration [50]. Ampicillin is mainly excreted by the kidneys,
and biliary excretion is of minor importance [51]. Thus, the ampicillin exposure of the gut
flora during parenteral administration seems far less than with per oral treatment. Some older
studies have shown increased prevalence of faecal ampicillin-resistant enterobacteria associ-
ated with intravenous administration of ampicillin in neonates [52, 53]. However, the studies
of the effect of aminopenicillin treatment on the gut flora have almost exclusively investigated
peroral drug administration [8]. Clinical studies comparing the impact of intravenous versus
peroral administration of antibiotics on the gut flora are lacking. The present study was not
designed to evaluate the effect of intravenous versus peroral administration of antibiotics on
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resistance in the faecal flora. Also, a comparison of the effect of antibiotic treatment in children
with CF (mainly oral) and children with cancer (mainly intravenous) on antibiotic resistance
in faecal bacteria could not be performed since these two groups represent very different dis-
eases and antibiotic treatment strategies, including spectre of antibiotics used and duration of
treatment. Repeated courses of antibiotics given to the children with CF from a young age
probably have an impact on the higher prevalence of faecal carriage of resistant enterobacteria
that was found in these children in our study.
Tetracycline-resistant E. coli and other Enterobacteriaceae were detected in all three study
groups (Table 3). Treatment with tetracycline is contraindicated in children below the age of
eight years due to the risk of discolouration of the teeth and effects on bone growth, and no
child in our study had ever been treated with tetracyclines. The high level of tetracycline resis-
tance without any apparent selection pressure from tetracycline exposure is indicative of trans-
fer of tetracycline-resistant strains and/or genetic elements from environmental sources.
Several studies have documented faecal carriage of tetracycline-resistant strains in children,
including infants [22, 54].
The prevalence of resistance to third-generation cephalosporins was not higher in the can-
cer group (in whom 66% of the children were treated for a median of 31 days per calendar year
with this class of antibiotics) as compared to the untreated healthy children. de Man et al.
detected a high risk of colonisation with enterobacteria resistant to cefotaxime in neonates
treated with intravenous amoxicillin plus cefotaxime [48]. Prevot et al. found that intestinal
colonization with cefotaxime-resistant Enterobacteriaceae in oncological patients was strongly
associated with individual exposure to cefotaxime [55]. Except for this, few studies have actu-
ally documented a correlation between third-generation cephalosporin treatment and faecal
carriage of resistance to these agents in individuals. The difference in the prevalence of third-
generation cephalosporin-resistant E. coli between the CF group and the control group barely
reached statistical significance in the last faecal sample (Table 3). The overall number of resis-
tant isolates was however low, and E. coli isolates carrying acquired ESBL genes were detected
in samples from only one single CF patient and from two cancer patients. The low level of
third-generation cephalosporin-resistance in E. coli as well as in other Enterobacteriaceae in
our study corresponds well with surveillance program reports from Norway during the same
time period [23]. We speculate that low resistance rates in the community may be of impor-
tance for the low level of selection of third-generation cephalosporin-resistant strains observed
in our two patient groups treated with these agents.
The prevalence of gentamicin resistance was low in all the study groups, including the
group of cancer patients in whom 84% of the children had been treated with aminoglycosides
for a median of 33.5 days per year in the study period. Aminoglycosides are primarily excreted
by the kidneys and less than 1% is eliminated in the faeces [56]. This may explain why no effect
of aminoglycoside treatment on enterobacterial resistance was detected in our study.
Samples growing Klebsiella spp. and some of the other non-E. coli enterobacterial species
were significantly more prevalent in the CF group compared to controls (Table 2). These spe-
cies are intrinsically resistant to some antibiotics, including ampicillin [57], and thus have a
selective advantage and may emerge during amoxicillin treatment.
Analyses of WGS data detected the presence of resistance determinants that explained the
observed phenotypic resistance in all 28 E. coli isolates examined in this study. This included
mutations (-42:C->T, -18:G->A) in the promoter region of the chromosomal ampC gene in
two isolates resistant to third-generation cephalosporins. The -42:C->T nucleotide change has
been shown to increase ampC expression 22-fold compared to wild-type E. coli [37]. Two pre-
viously described gyrA mutations and one or two parC mutations were detected in all the cip-
rofloxacin-resistant isolates (Table 6 and S4 Table); in accordance with other studies that
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reported that more than one gyrA mutation confer phenotypic ciprofloxacin resistance [40,
58].
The MLST-analyses showed no clustering of isolates that could indicate patient-to-patient
transfer or an outbreak. The observation of E. coli isolates of different STs in the same patient,
all harbouring blaCTX-M-1, indicates transfer of a mobile genetic element carrying this resis-
tance gene between E. coli strains in the gut of the individual patient. This within-host diversity
has previously been shown for ESBL-producing E. coli [59, 60].
Our study has some limitations. The children with cancer comprised a very heterogeneous
group of malignant diseases that vary in treatment intensity and duration. This probably influ-
ences the risk of acquiring infections and the level of antibiotic exposure within this study
group. The number of individuals within each of the different malignancies was too small to
perform subgroup analyses of antibiotic exposure and resistance. Further, we cannot exclude
that repeated exposures to cytostatic chemotherapy per se also have an impact on the gut flora,
including the level of resistance. Studies on this issue are lacking, although some researches
have studied the effects of antineoplastic drugs, alone or in combination with antibiotics, on
bacterial growth in vitro, with conflicting results [61–64].
The faecal samples in this study were collected several years ago, and an obvious limitation
of our study is lack of data from the present time period. However, the low level of resistance
in Norway at the time of the study [23], allowed us to evaluate the impact of the antibiotic
treatment with minor influence of influx of resistance from the surroundings. Nevertheless, a
replication of such a study in Norway at present would be of great interest. Another limitation
of the study is the comparatively small number of children with CF and cancer included, both
being relatively rare diseases. Thus, the lack of statistically significant correlations between
antibiotic treatment and occurrence of antibiotic resistance in our study may be due to too low
power to study the effect of exposure to each individual antibiotic within each patient group.
Conclusions
In this study we found that the prevalence of faecal carriage of enterobacteria resistant to ampi-
cillin and trimethoprim-sulfamethoxazole was significantly higher in children with CF as com-
pared to healthy children. A likely explanation is a selection pressure from treatment with
large amounts of these antibiotics in the CF patients. However, the prevalence of resistant fae-
cal enterobacteria was not higher in children with cancer after repeated courses of mainly
intravenous antibiotic treatment compared to healthy children with no or a very low level of
antibiotic exposure. The level of enterobacterial resistance to third-generation cephalopsorins,
ciprofloxacin and gentamicin was low in all three study groups. We speculate whether the
mode of administration of antibiotics and the level of antimicrobial resistance in the com-
munity may have an impact on emergence of resistance in intestinal enterobacteria during
antibiotic treatment. Further studies comparing the effect of intravenous versus peroral
administration of antibiotics on the gut flora are needed to assess such a hypothesis. WGS
analyses detected acquired resistance genes and/or chromosomal mutations that explained the
observed phenotypic resistance in 28 examined multidrug-resistant E. coli isolates.
Supporting information
S1 Data. Epidemiology and faecal sample results.
(SAV)
S1 Table. Assembly data from 28 whole genome sequenced E. coli isolates.
(XLSX)
Antibiotic treatment and faecal carriage of antibiotic-resistant enterobacteria in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0187618 November 7, 2017 13 / 18
S2 Table. Antibiotic treatment in 31 children with cystic fibrosis and 44 children with can-
cer.
(DOCX)
S3 Table. Antibiotic treatment among 33 of the 70 healthy controls.
(XLSX)
S4 Table. Sequence type, phenotypic resistance patterns and corresponding genetic resis-
tance determinants in 28 Escherichia coli isolates from faecal samples from children with
cystic fibrosis and cancer and healthy controls.
(XLSX)
S5 Table. Molecular investigation of Enterobacteriaceae isolates (non-E. coli) with reduced
susceptibility to third-generation cephalosporins.
(DOCX)
Acknowledgments
We thank Kristian Alfsnes, May-Liss Funke and André Ingebretsen for technical expertise and
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